

# Proctological oblivion

## Citation for published version (APA):

Kuiper, S. Z., Dirksen, C. D., & Breukink, S. O. (2021). Proctological oblivion. *Colorectal Disease*, 23(3), 573-573. <https://doi.org/10.1111/codi.15595>

## Document status and date:

Published: 01/03/2021

## DOI:

[10.1111/codi.15595](https://doi.org/10.1111/codi.15595)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## Proctological oblivion

Who could ever imagine that proctological complaints could be a true gamechanger? A striking example is the saga around the loss of Napoléon Bonaparte at the battle of Waterloo where his anal ailments may have hampered a military success.

However, not only emperors suffer from proctological diseases; the prevalence of anal symptoms ranges up to 15% in general practice [1]. If compared with the prevalence figures of patients having Inflammatory Bowel Disease (IBD), ranging around 0.3%, the former is a noticeably larger group [2].

Despite the high prevalence and noteworthy negative impact of proctological illnesses on quality of life, the level of evidence in this field remains generally very low. This observation was confirmed by the recently published European Society of ColoProctology (ESCP) guideline regarding the treatment of haemorrhoidal disease (HD) [3]. Moreover, the same pattern of robust research deficit is seen in other areas in the territory of proctology, i.e., faecal incontinence, perianal fistula and anal fissure. The term 'proctology' touches not even 80,000 hits on PubMed, compared to over 108,000 results for the much smaller population of IBD patients. Although the disease burden of coloproctological complaints on a patient level may be limited, the disease burden on a population level is huge; the same holds true regarding the economic burden [4].

Hence, the question rises why this imbalance in research exists and secondly how can we overcome this?

A solution may be to prioritise proctology on the research agendas of different (inter)national forums. As a result, more high-quality studies can be designed and conducted to raise the level of robust evidence.

In these trials we endorse the use of patient-centred outcomes as primary outcome measures, complemented by traditional clinical outcomes such as recurrence of disease, complications and duration of operation. Selecting only traditional clinical outcomes in proctology may not represent treatment success as experienced by patients. This venture was underwritten by the ESCP in the publication of a Core Outcome Set (COS) for HD; in this COS, 'patient-reported symptoms' was the item selected as the primary outcome [5]. Using a COS will also improve transparency between studies and facilitate

the ability to compare and combine (future) studies. The development of a COS for other proctological diseases has also been set in motion. Furthermore, it is advised to perform cost-effectiveness studies alongside such trials to gain more insight in the costs and savings associated with effective treatment options. Considering the large numbers of patients involved in the management of proctological complaints, there is much to gain regarding efficient use of resources on a patient and population level.

Eventually these clinical trials in proctology, will allow proper evidence synthesis and improve evidence-based guidelines and clinical practice. This may seem like a small and obvious step, but it will mean a huge leap in reducing the human and economic burden of proctological disease.

Sara Z. Kuiper  
Carmen D. Dirksen  
Stéphanie O. Breukink  
Email: s.breukink@mumc.nl

### REFERENCES

1. Tournu G, Abramowitz L, Couffignal C, Juguet F, Sénéjoux A, Berger S, et al. Prevalence of anal symptoms in general practice: a prospective study. *BMC Family Practice*. 2017;18(78):1-7.
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *The Lancet*. 2017;390(10114):2769-78.
3. Van Tol RR, Kleijnen J, Watson AJM, Jongen J, Altomare DF, Qvist N, et al. European Society of ColoProctology: guideline for haemorrhoidal disease. *Colorectal Dis*. 2020;22(6):650-62.
4. Yang JY, Peery AF, Lund JL, Pate V, Sandler RS. Burden and cost of outpatient hemorrhoids in the United States Employer-insured population, 2014. *Am J Gastroenterol*. 2019;114:789-803.
5. Van Tol RR, Kimman ML, Melenhorst J, Stassen LPS, Dirksen CD, Breukink SO, et al. European Society of ColoProctology Core Outcome Set for haemorrhoidal disease: an international Delphi study among healthcare professionals. *Colorectal Dis*. 2019;21(5):570-80.